Back to search

Article

Paclitaxel Resistance in Ovarian Cancers Relies on a PGAM1 Mediated Glycolytic Metabolism

2020-11-09

Abstract excerpt

<title>Abstract</title> <p>Background: Paclitaxel, as an anti-microtubule drug, has been recommended to be the first-line chemotherapy agent for ovarian cancer for about two decades. However, most patients with advanced stage relapse within two years and ultimately die of relapsed cancer displaying increased chemoresistance. The mechanisms underlying paclitaxel resistance remain ncompletely understood. <h4>Method...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1adcdb2a-4728-5487-913a-5eba8e5fc78e
DOI
10.21203/rs.3.rs-103118/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Paclitaxel Resistance in Ovarian Cancers Relies on a PGAM1 Mediated Glycolytic MetabolismDOI 10.21203/rs.3.rs-103118/v1
Select a neighboring publication to make it the new centre.